Potential of immuno-oncology therapies to selectively identify and attack the cancer cells which reduces the side effects is intended to take the global market for immuno-oncology to a new high in the coming future. Immuno-oncology therapies target the immune system of the body and not the tumor, by activating immune system to recognize the cancer cell and kill them by natural mechanism. These immuno-oncology therapies are becoming choice of therapy by oncologists as they provide long lasting effects such that the body can adapt to the changing behavior (resistance) of cancer cells toward immune system and improve the quality survival. Commercial immuno-oncology therapies are available against cancer types such as prostate cancer and melanoma and many other are under clinical studies. Some of the available immuno-oncology therapies include Zaltrap, Keytruda, Opdivo, Yervoy, Imlygic, Zyclara and others. Cancer treatment vaccines are currently being developed which can enhance the immune system’s response to tumor cell. Some of the FDA approved cancer treatment vaccines include Sipuleucel-T, bacillus Calmette-Guérin (BCG) etc.
Effective mechanism of immuno-oncology therapies for the patient with poor prognosis is expected to drive the growth of immuno-oncology market. The evidences from clinical trials reveals that the effects of immuno-oncology therapies on cancer cells would last for a longer time by preparing the immune system to fight against cancer cells even after the reduction in tumor cells. Additionally the side-effects associated with immuno-oncology therapies are limited as compared to many other cancer therapies, which creates a positive impact on the growth of immuno-oncology market. The restraining factors for the immuno-oncology therapies market are high cost of treatment, lack of awareness and slower pipeline development
The global immuno-oncology market has been classified on the basis of product type, end user and geography.
Based on product type, the global immuno-oncology market is segmented as follows:
- Monoclonal Antibodies (mAb)
- Antibody Drug Conjugates
- Cancer Treatment Vaccines
- Chimeric Antigen Receptor (CAR) T-Cell Therapies
- Interferon and Cytokine therapies
- PD-1/PD-L1 inhibitors
Based on end user, the global global immuno-oncology market is segmented as follows:
- Cancer Research Centers and Institutes
Extensive scope of immuno-oncology agents in various cancer treatments would provide maximum share to immuno-oncology treatment in overall cancer drug market during the forecast period. This lucrative opportunities in immuno-oncology treatment would provide boost to the product development during the forecast period. The slower pace of research and development activities and capital intense investment in manufacturing are the factors extending the commercialization of immuno-oncology therapies. However, lesser side effects associated with immunological treatments and better efficacy is expecting to get positive response from the cancer specialists after commercialization of immuno-oncology therapies.
Geographically, the global Immuno-oncology therapies market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America and Europe are the lucrative regions for immuno-oncology market due to their potential to invest the huge amount of money in the development of immuno-oncology therapies and availability of better reimbursement policies. Moreover, affordability for the cost of treatment is also high in North America and Europe. The global immuno-oncology market is expected to grow during the forecast period due to increasing investment by multinational companies in the cancer research
Some of the key players in global immuno-oncology market are Seattle Genetics, Inc., Genentech, Inc., F. Hoffmann-La Roche Ltd., Eisai Co. Ltd., Amgen Inc., Bayer AG, Sanofi Aventis LLC., Merck & Co., Inc., Bristol-Myers Squibb Company, Dendreon Corporation and others. The global immuno-oncology market is expected to grow during the forecast period due to increasing investment by multinational companies in the cancer research.
To View TOC of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/toc/11329
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type of product and applications.
Buy Now: You can now buy a single user license of the report at http://www.persistencemarketresearch.com/checkout/11329
The final report customized as per your specific requirement will be sent to your e-mail id within 7-20 days, depending on the scope of the report.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
For more information, please e-mail us at email@example.com